Neurotransmitters and receptors: clinical implications.
With the advent of new techniques such as the radioreceptor binding assay, significant advances have been made in the field of psychopharmacology during the past seven years. In this paper we discuss some of these contributions regarding our understanding about the nature of different psychopathological conditions such as anxiety, depression and schizophrenia.
D001007:Anxiety / Q000378:metabolism; D001665:Binding Sites; D003866:Depressive Disorder / Q000378:metabolism; D006801:Humans; D007099:Imipramine / Q000378:metabolism; D001523:Mental Disorders / Q000188:drug therapy / Q000503:physiopathology*; D018377:Neurotransmitter Agents / Q000378:metabolism*; D011956:Receptors, Cell Surface / Q000378:metabolism; D011954:Receptors, Dopamine / Q000502:physiology; D011963:Receptors, GABA-A; D017981:Receptors, Neurotransmitter / Q000502:physiology*; D012559:Schizophrenia / Q000503:physiopathology
D018377:Neurotransmitter Agents; D011956:Receptors, Cell Surface; D011954:Receptors, Dopamine; D011963:Receptors, GABA-A; D017981:Receptors, Neurotransmitter; D007099:Imipramine